Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting.
Xin
X
Zhou
Jianping
J
Zhu
Hongli
H
Sun
Lizheng
L
Shao
Ming
M
Xu
Hongfeng
H
Guo
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003131:Combined Modality Therapy; D055612:Cytokine-Induced Killer Cells / Q000637:transplantation*; D006801:Humans; D016219:Immunotherapy, Adoptive; D008297:Male; D009101:Multiple Myeloma / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib